Taking a historical perspective, we review the discovery, pharmacology, and clinical
evaluation of the old and new anticoagulants that have been approved for clinical use. The …

Introduction Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce
bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) …

Abstract Background In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During
Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2-to 4-hour high …

Heparin, a naturally occurring polysaccharide, has fascinated researchers and clinicians for
nearly a century due to its versatile biological properties and has been used for various …

Background Conflicting results comparing bivalirudin versus heparin anticoagulation in
patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …

Platelets are central to thrombosis. Research at the intersection of biological and physical
sciences provides proof-of-concept for shear rate-dependent platelet slip at vascular …

The development of novel anticoagulants requires a comprehensive investigational
approach that is capable of characterizing different aspects of antithrombotic activity. The …

Introduction In clinical practice, the dose of bivalirudin may not be fully applicable to the
Chinese population. Therefore, this study aimed to explore the efficacy and safety of a …

Aims The present meta-analysis focused on investigating whether bivalirudin plus post-PCI
infusion was safer and more effective than heparin monotherapy in patients who developed …

Managing antithrombotic therapy in patients undergoing complex and high-risk in indicated
patients, including those treated with complex percutaneous coronary intervention (PCI) or …